Symposium 11: Modern teaching of Pharmacoepidemiology in a 'Big Data' World

Moderator

Robert W. Platt, McGill University, Canada

Robert Platt is Professor in the departments of Pediatrics and of Epidemiology, Biostatistics, and Occupational Health (EBOH) at McGill University, and Director of Graduate Programs in the department of EBOH. He is a Senior Investigator at the Research Institute of the McGill University Health Centre and the Lady Davis Institute of the Jewish General Hospital, and Investigator at the McGill Pharmacoepidemiology Research Unit. He holds the Albert Boehringer I endowed chair in Pharmacoepidemiology. Dr. Platt is the Executive Co-Lead and leader of the Methods team of the Canadian Network for Observational Drug Effect Studies (CNODES). His research focuses on improving methods for the study of medications using administrative data, with an emphasis on methods for causal inference. His substantive research focuses on studies in pregnancy. Dr. Platt is on the editorial board of the American Journal of Epidemiology, Pharmacoepidemiology and Drug Safety and Current Epidemiology Reports, and is Associate Editor of Statistics in Medicine and the International Journal of Biostatistics. He has published over 300 articles, one book and several book chapters on epidemiology.

Speakers

Kristian Filion, McGill University, Canada

Dr. Filion is a tenured Associate Professor of Medicine and of Epidemiology, Biostatistics, and Occupational Health at McGill University, an Investigator at the Center for Clinical Epidemiology of the Lady Davis Institute of the Jewish General Hospital, and an Investigator at the McGill Pharmacoepidemiology Research Unit. He is a Steering Committee member and Co-Lead of the Clinical Practice Research Datalink (CPRD) Team of the Canadian Network for Observational Drug Effect Studies (CNODES), a pan-Canadian drug safety network that addresses emerging questions of drug safety and effectiveness posed by government stakeholders such as Health Canada. He leads an independent research program focused on the use of large, population-based databases to study the effectiveness, safety, and utilization of prescription drugs in real-world settings with a substantive focus on cardiometabolic conditions including cardiovascular disease and diabetes. He is a Fellow of the American Heart Association. Dr. Filion is a member of the Permanent Scientific Committee for the Evaluation of Medications of the Institut national d'excellence en santé et en services sociaux (Quebec's health technology assessment agency), which helps inform policy regarding which drugs should be listed in Quebec's provincial drug formulary. He has published over 130 peer-reviewed publications.

Seoyoung C. Kim, Harvard Medical School, USA

Seoyoung C. Kim, MD, ScD., MSCE is an Associate Professor of Medicine at Harvard Medical School and the Director of the Program in Rheumatologic, Immunologic and Musculoskeletal PharmacoEpidemiology (PRIME) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital (BWH). She is board-certified rheumatologist and co-appointed in the Division of Rheumatology at BWH. Her research focuses on comparative safety and effectiveness of opioids, biologic or conventional immunosuppressive drugs used in various rheumatic diseases. Her research work is primarily funded by the NIH and investigator-initiated research grants from industry. She is an Associate Editor for Arthritis Care & Research and ACR Open Rheumatology and serve as a Special Government Employee for the U.S. FDA Arthritis Advisory Committee. She serves on the Drug Safety Monitoring Board as a Safety Officer for an NIH-funded clinical trial of certolizumab.

After graduating from Hanyang University College of Medicine in Korea, she completed the internal Medicine residency at the State University of New York at Buffalo and the rheumatology fellowship training at the University of Pennsylvania and BWH. She received a master's degree in Clinical Epidemiology at the University of Pennsylvania and a doctoral degree in Epidemiology at Harvard Chan School of Public Health.

Nicole Pratt, University of South Australia, Australia

Dr Nicole Pratt is an Associate Professor and Deputy Director of the Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia. She is a member of the Drug Utilisation Subcommittee (DUSC) of the Australian Department of Health Pharmaceutical Benefits Advisory Committee (PBAC). Nicole leads the evaluation of the Department of Veterans Affairs, Veterans' Medicines Advice and Therapeutics Education Service (Veterans' MATES) program which uses administrative claims data to develop and evaluate interventions to improve use of medicines in the veteran population in Australia. She is a past-chair of the Asian Pharmacoepidemiology Network (AsPEN) initiative (www.aspennet.asia) and a collaborator of Observational Health and Data Sciences and Informatics (www.ohdsi.org) which aims to bring out the value of health data through large-scale analytics.

Rae Woong Park, Ajou University, South Korea

Prof. Rae Woong Park is the Director and Professor of the Department of Biomedical Informatics at Ajou University School of Medicine, South Korea, and Chairman of board of The Korean Society of Medical Informatics (KOSMI). He graduated Ajou University Medical School (1995)

Dr Park is an active international collaborator of OHDSI. He has devoted himself as a missionary of Common Data Model (CDM) in Korea. Now OMOP-CDM has adopted as major healthcare research standard and platform in South Korea

He in charge of FEEDERNET (Federated E-health Big Data for Evidence Renovation Network), a 3-year research project (2018-2022) granted from government. The total budget of the project is about 20M USD. Sixty-two largest Korean hospitals joined the FEEDERNET and he is converting the participating hospitals' EHR data into CDM and developing a cloud research platform that works on the CDM network. He enormously contributed to let Korean government raise new > 30 research grants on CDM (2018-2022) with total budget of 40M USD.